Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (heme arginate) presented as an injectable solution for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyrias by supplying exogenous heme to patients experiencing metabolic crises.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing regulated distribution to healthcare facilities across multiple regions while ensuring product quality and compliance with global standards.

Normosang is used in the management of acute hepatic porphyria disorders, where it restores heme levels to control disease activity.

Acute intermittent porphyria: reduces accumulation of neurotoxic porphyrin precursors and alleviates attack symptoms. Hereditary coproporphyria: provides heme feedback inhibition to decrease ALA and PBG production. Variegate porphyria: helps terminate acute attacks by replenishing hepatic heme stores.

Administration of Normosang may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion site pain: discomfort at the injection site. - Phlebitis: inflammation of the vein used for infusion. - Nausea: feeling of sickness or urge to vomit. - Fever: elevated body temperature during or after infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hemolysis: destruction of red blood cells that can lead to anemia. - Severe hypotension: marked drop in blood pressure during infusion. - Hepatic dysfunction: impaired liver function indicated by abnormal enzyme levels.

Prior to initiating Normosang therapy, several precautionary measures should be considered to ensure patient safety.

Assess hypersensitivity: verify no known allergy to hemin or formulation components. Monitor liver function: perform baseline and periodic hepatic enzyme tests. Evaluate for G6PD deficiency: avoid use in patients with known deficiency due to hemolysis risk. Use cautiously in renal impairment: adjust monitoring as drug clearance may be affected. Avoid concurrent porphyrinogenic drugs: discontinue or substitute agents that can precipitate attacks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Porphyrinogenic drugs (e.g., barbiturates, sulfonamides, antiepileptics): may trigger or worsen porphyria attacks. - Anticoagulants (e.g., warfarin): hemin may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Other heme preparations: concurrent use may cause heme overload and hepatic strain. - Oral contraceptives: may alter heme metabolism, requiring clinical observation. - Anticonvulsants (e.g., phenytoin, carbamazepine): monitor liver enzymes for potential hepatotoxicity.